[13,20,22-Trihydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-19-(prop-2-enylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18(22),19-hexaen-9-yl] carbamate | 857402-23-4

• 物质功能分类: 生物化工 - 生化试剂 - 激动剂抑制剂
• 分子结构分类: 有机化合物 - 苯丙烷和聚酮 - 大环内酰胺类
• 英文名称: [13,20,22-Trihydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-19-(prop-2-enylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18(22),19-hexaen-9-yl] carbamate
• 英文别名: [13,20,22-trihydroxy-8,14-dimethoxy-4,10,12,16-tetramethyl-3-oxo-19-(prop-2-enylamino)-2-azabicyclo[16.3.1]docosa-1(21),4,6,10,18(22),19-hexaen-9-yl] carbamate
• CAS: 857402-23-4
• 化学式: C₃₁H₄₅N₃O₈
• 分子量: 587.7
• InChiKey: OAKGNIRUXAZDQF-UHFFFAOYSA-N

物化性质

• 沸点：
  800.9±65.0 °C(Predicted)
• 密度：
  1.23
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  3.4
• 重原子数：
  42
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.48
• 拓扑面积：
  173
• 氢给体数：
  6
• 氢受体数：
  9

安全信息

• 储存条件：
  2-8℃

制备方法与用途

Retaspimycin 是一种有效且水溶性的Hsp90抑制剂，其对Hsp90和Grp9的EC50值均为119纳摩尔。

文献信息

• Methods and compositions for treating urea cycle disorders
  申请人：Camp4 Therapeutics Corporation

  公开号：US11266655B2

  公开（公告）日：2022-03-08

  Provided are methods and compositions for the treating a patient with a urea cycle disorder. Methods and compositions are also provided for modulating genes encoding enzymes that participate in the urea cycle by altering gene signaling networks.

  本文提供了治疗尿素循环障碍患者的方法和组合物。还提供了通过改变基因信号网络来调节编码参与尿素循环的酶的基因的方法和组合物。
• METHODS AND COMPOSITIONS FOR TREATING UREA CYCLE DISORDERS, IN PARTICULAR OTC DEFICIENCY
  申请人：CAMP4 THERAPEUTICS CORPORATION

  公开号：US20200316038A1

  公开（公告）日：2020-10-08

  The present invention provides methods and compositions for the treating a patient with a urea cycle disorder. Methods and compositions are also provided for modulating genes encoding enzymes that participate in the urea cycle by altering gene signaling networks.
• METHODS AND COMPOSITIONS FOR TREATING UREA CYCLE DISORDERS
  申请人：Camp4 Therapeutics Corporation

  公开号：US20210114996A1

  公开（公告）日：2021-04-22

  Provided are methods and compositions for the treating a patient with a urea cycle disorder. Methods and compositions are also provided for modulating genes encoding enzymes that participate in the urea cycle by altering gene signaling networks.